<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Letters to the Editor Sialylation of IgG antibodies inhibits IgG-mediated allergic reactions</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<title level="a" type="main">Letters to the Editor Sialylation of IgG antibodies inhibits IgG-mediated allergic reactions</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">AC3AF6ED869944D4188764436FB73C90</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:26+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract/>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>To the Editor:</s></p><p><s>E6-E12 The effector functions of IgG antibodies depend on their subclass <ref type="bibr">E11,E13</ref> and the type of Fc N-glycosylation (Fig <ref type="figure" target="#fig_6">1, A</ref>, and see Fig E1 in this article's Online Repository at www.jacionline.</s><s>org).</s><s>E15-E19 However, the effects of IgG subclasses and Fc glycosylation patterns in allergy remain unclear.</s></p><p><s>We first compared the capacity of differently glycosylated forms of murine IgG 1 , a subclass that resembles AIT-induced human IgG 4 in its limited ability to activate complement and classical activating FcgRs, <ref type="bibr">3,E1,E5,E11,E13</ref> to inhibit IgE-mediated systemic anaphylaxis (Fig 1 <ref type="figure">, B-E</ref>, and see Fig <ref type="figure" target="#fig_6">E1 and</ref> the Methods section in this article's Online Repository at www. jacionline.org).</s><s>IgE-mediated anaphylaxis (assessed as decreased rectal temperature) was induced intravenously with 10 mg of IgE anti-2,4,6-trinitrophenyl (TNP) mAbs, followed by an intravenous challenge 24 hours later with 1 mg of TNP-coupled ovalbumin (TNP-OVA; Fig 1, B). Increasing doses of differently glycosylated murine IgG 1 anti-TNP mAbs (clone H5; native 5 low-galactosylated, in vitro galactosylated, or in vitro galactosylated plus sialylated) decreased IgE-mediated hypothermia in an FcgRIIb-dependent manner (Fig 1 <ref type="figure">, B-E</ref> Even though low-galactosylated IgG 1 showed a tendency for more efficient inhibition (Fig 1 <ref type="figure">, C</ref>; 3 mg of IgG 1 ; not significant), possibly because of its higher affinity than sialylated IgG 1 for FcgRIIb, <ref type="bibr">E16</ref>  In contrast, the severity of IgG-mediated systemic anaphylaxis, which required challenge with a higher antigen dose (20 mg), <ref type="bibr" target="#b1">2,</ref><ref type="bibr" target="#b2">3</ref> was IgG subclass-and glycosylation-dependent (  <ref type="bibr">7,8,E17,E18</ref> These observations suggest that AIT protocols that promote sialylation of human IgG 4 might optimally limit the possibility of IgG-mediated systemic anaphylaxis in the presence of higher allergen doses.</s></p><p><s>E21-E23 In untreated patients Bet v 1-specific IgG 4 titers were constantly low, whereas IgE and IgG 1 titers increased during the pollen season (Fig 2 <ref type="figure">, A</ref>, and see Fig E2).</s><s>E21,E22,E24 However, the Fc glycosylation profile of Bet v 1-specific serum IgG antibodies from untreated and AIT-treated patients remained stable and was more highly galactosylated and sialylated than that of IgG autoantibodies from patients with rheumatoid arthritis (Fig 2, B and C, and see Fig E2).</s><s><ref type="bibr">E14</ref> The glycosylation profiles of the AIT-treated patients resembled those of 2 recently described patients with AIT who had received similar therapy with alum (Allergovit; Allergopharma, Reinbek, Germany) <ref type="bibr" target="#b4">5</ref> and of those in therapeutic intravenous immunoglobulin (IVIG), which have Fc sialylation-dependent anti-inflammatory properties (Fig 2, B  and C, and see Fig E2).</s><s><ref type="bibr">E16-E18</ref> Consistent with an inverse relationship between IgG sialylation and inflammatory potential, we found that desialylation of native Bet v 1-specific IgG from the sera of AIT-treated patients strongly increased its ability to activate neutrophils in vitro (Fig 2 <ref type="figure">, B-E</ref>, and see Fig E2).</s></p><p><s>These observations suggest that conventional AIT with alum induces sialylated IgG (4) antibodies that probably have low potential to induce IgG-mediated allergic reactions.</s><s>However, studies remain required to assess how Fc glycosylation modulates the effector functions of human IgG 1 and IgG 4 and how new AIT protocols with distinct adjuvants 1,E25-E29 will influence the human IgG subclass distribution and Fc glycosylation pattern and, consequently, the risk of IgG-mediated allergic reactions.</s><s>To initiate such studies, we compared the effects of enriched complete Freund adjuvant (eCFA; highly inflammatory), alum, and monophosphoryl lipid A (MPLA; recently approved for AIT) <ref type="bibr">1,6,E26,E27</ref>  In contrast to only small differences in the Fc glycosylation pattern between human IgG subclasses in the same sample, <ref type="bibr">E30,E31</ref> glycopeptide analysis confirmed that murine IgG 2 (IgG 2b and IgG 2c ) was, on average, much more highly galactosylated and sialylated than IgG Taken together, our data suggest that although IgG subclass and glycosylation patterns have relatively little effect on IgG antibody blocking of IgE-mediated anaphylaxis, increased sialylation of IgG(4) antibodies should decrease the risk of IgG-induced anaphylaxis in the presence of high allergen doses.</s><s>[d] 0 Balb/c wt or Fcgr2b-/mice body core temp.</s></p><p><s>x µg differently glycosylated anti-TNP IgG i.v. ( ) ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( )  Accordingly, it seems advisable to select adjuvants for new AIT protocols <ref type="bibr">1,E25,E26</ref> for their ability to promote sialylated IgG(4) antibody responses.</s></p><formula xml:id="formula_0">) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) Asn 297 ( ) G0 G1 G2 G1S1 G2S1 G2S2</formula><p><s>The murine IgG 1 , IgG 2a , and IgG 2b anti-TNP hybridoma switch variants were a gift from Lucien Aarden (Amsterdam, The Netherlands), and the murine IgG 1 anti-TNP (clone H5) hybridoma cell line was from Birgitta Heyman (Uppsala, Sweden).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Alexandra Epp, MSc</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Effect of home exposure to</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Staphylococcus aureus on asthma in adolescents</head><p><s>To the Editor:</s></p><p><s>Asthma is a major public health problem, particularly among inner-city minority children and adolescents.</s><s>Indoor home environmental exposures to allergens and gram-negative endotoxin are established drivers of asthma morbidity in this population. <ref type="bibr" target="#b0">1</ref></s><s>Although there has been recent interest in whether microbial dysbiosis can drive asthma morbidity, less is known about the role of specific environmental bacteria in asthma.</s><s>One bacterium that can affect asthma control through environmental exposure is the Gram-positive Staphylococcus aureus, which often persists on surfaces and in home dust. <ref type="bibr" target="#b1">2</ref> Colonization with S aureus is known to worsen eczema and has been linked to</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Human samples</head><p><s>Serum samples of 7 patients (P2, P5, P7, P8, and P11-P13) from a previously published cohort of 15 patients <ref type="bibr">E21-E23,E33</ref> and 4 additional patients (P19-P22) who completed a 3-year subcutaneous AITwith birch pollen extract containing alum (ALK-depot SQ; ALK-Abell o) were investigated.</s><s>Before treatment, all 11 patients had allergic symptoms to birch pollen (rhinoconjunctival symptoms with or without asthma) and were characterized by a positive skin prick test response with birch pollen extract (ALK Prick SQ; ALK-Abell o), total serum IgE concentrations, and serum IgE reactivity against both birch pollen extract and Bet v 1 (kU A /L; Phadia ImmunoCAP System; Thermo Fisher, Uppsala, Sweden; Fig 2, and Figs E2 and E4).</s><s>The studies were approved by the Ethics Committee of the Medical Faculty of Philipps University, Marburg, Germany; all patients provided written informed consent to participate in the trials.</s><s>Additionally, sera from untreated patients with moderate-to-severe birch pollen allergy symptoms were collected during (n 5 8) or outside (n 5 8) the birch pollen season (Fig E4)  after patients provided written informed consent (Ethics Committee of the Medical Faculty of the University of L€ ubeck; approval no.</s><s>12-042).</s><s>Bet v 1-specific IgE, IgG, IgG 1 , and IgG 4 titers of untreated (season, n 5 8; no season, n 5 6) and all treated patients and Fc glycosylation profiles of purified Bet v 1-specific IgG antibodies from 10 of the 16 untreated patients during (n 5 5) or outside (n 5 5) the birch pollen season and 5 randomly selected treated patients (P2, P11, P13, P19, and P21) at different time points (Fig 2  and Figs E2 and E4) were analyzed.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Mice</head><p><s>All mice were bred and maintained in the specific pathogen-free facilities at the University of L€ ubeck or the Cincinnati Children's Research Foundation, and all experiments were done with approval of and in accordance with regulatory guidelines and ethical standards set by the University of L€ ubeck and the Ministry of Schleswig-Holstein, Germany, or the Institutional Animal Care and Use Committee of Cincinnati Children's Hospital Medical Center, respectively.</s><s>BALB/c and C57BL/6 wild-type mice were purchased from Charles River Laboratories (Malvern, Pa).</s><s>Fcgr2b 2/2 mice had been backcrossed for a minimum of 10 generations to the BALB/c or C57BL/6 background.</s><s><ref type="bibr">E34</ref> Only 8-to 12-week-old female mice were analyzed in the experiments.</s><s>Mice were randomly assigned to groups, but a specific randomization program was not used.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reagents</head><p><s>TNP-coupled BSA (TNP-BSA), BSA, and TNP-OVA were purchased from Biosearch Technologies (Novato, Calif), and OVA was purchased from Sigma-Aldrich (St Louis, Mo).</s><s>Incomplete Freund adjuvant was purchased from Sigma-Aldrich.</s><s>eCFA was prepared by adding heat-killed Mycobacterium tuberculosis H37 RA (DIFCO Laboratories, Oxford, United Kingdom) to incomplete Freund adjuvant (5 mg of Mycobacterium tuberculosis/mL).</s><s><ref type="bibr">E35</ref> Alum was purchased from Thermo Scientific (Waltham, Mass), MPLA was derived from Salmonella minnesota R595 (MPLA-SM; # vac-mpla; InvivoGen, San Diego, Calif) and IVIG (Intracet from Biotest [Boca Raton, Fla]; pooled serum IgG of healthy donors used in high concentrations [2 g/kg] to treat patients with acute flares of autoimmune disease).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>mAbs</head><p><s>The IgE anti-TNP (clone IgEL a2; ATCC-TIB-142) <ref type="bibr">E36</ref> and IgG 1 anti-TNP (clone H5) <ref type="bibr">E35,E37</ref> hybridoma cells and the murine IgG 1 , IgG 2a , and IgG 2b anti-TNP hybridoma switch variants with identical V(D)J sequences E20 were authenticated by using an antigen-specific IgG subclass ELISA and grown in 0.03% Primatone RL/UF (175#DR from Kerry Biosciences, Tralee, Ireland) for antibody production.</s><s>The IgG hybridoma cell lines had negative test results for Mycoplasma species contamination.</s><s>IgG mAbs were purified from cell culture medium with Protein G-Sepharose (GE Healthcare, Little Chalfont, United Kingdom), and IgE anti-TNP mAbs were purified with TNP-BSA coupled to cyanogen bromide (CNBr)-activated Sepharose 4B (GE Healthcare) prepared in our laboratory.</s><s>Antibody integrity was verified by using SDS-PAGE, and anti-TNP reactivity was tested with ELISA.</s><s>IgG Fc glycan structures were analyzed by means of HPLC.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunization and purification of OVA-specific IgG antibodies</head><p><s>Eight-to 10-week-old C57BL/6 mice were immunized intraperitoneally, as indicated in Fig 2, F, and Fig E3.</s><s>Serum samples were collected on day 14, and pooled OVA-specific serum IgG antibodies were purified with OVA coupled to CNBr-activated Sepharose 4B (GE Healthcare) prepared in our laboratory.</s><s>Enrichment of OVA-specific IgG antibodies was verified by using ELISA.</s><s>IgG subclass distribution and Fc glycan structures were analyzed by means of glycopeptide and IgG glycan HPLC analysis.</s><s>The potential of the pooled and purified IgG anti-OVA antibodies from distinct groups was analyzed in the IgG-mediated anaphylaxis model.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recombinant Bet v 1</head><p><s>Recombinant Bet v 1-A (Bet v 1.0101; www.allergen.org)</s><s>was expressed in Escherichia coli BL21 cells (Merck Millipore, Darmstadt, Germany) in the form of inclusion bodies.</s><s>Inclusion bodies were solubilized with 6 mol/L guanidine hydrochloride, and Bet v 1 was subsequently refolded by means of rapid dilution in sodium phosphate buffer (pH 7.2).</s><s>Folded Bet v 1 was purified by means of hydrophobic interaction chromatography (phenyl Sepharose 6FF high sub; GE Healthcare) and size exclusion chromatography (Superdex 75; GE Healthcare) and finally formulated in 18 mmol/L sodium phosphate, 135 mmol/L sodium chloride, and 10% glycerol.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Purification of Bet v 1-specific IgG antibodies</head><p><s>Human serum IgG was purified with Protein G-Sepharose (GE Healthcare).</s><s>Bet v 1-specific IgG was enriched with Bet v 1 coupled to CNBr-activated Sepharose 4B (GE Healthcare) prepared in our laboratory (Fig E2).</s><s>Enrichment of Bet v 1-specific IgG and exclusion of tetanus toxin-specific IgG was verified by using ELISA (Fig E2).</s><s>IgG Fc glycan structures were analyzed by using HPLC.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>TNP-and OVA-reactive ELISA</head><p><s>ELISA plates were coated with 10 mg/mL TNP-BSA or OVA with or without the indicated concentrations of BSA to measure the reactivity or affinity of the indicated IgG subclass anti-TNP mAbs or (purified) serum IgG anti-OVA antibodies.</s><s>Bound antibodies were detected with horseradish peroxidase-coupled polyclonal goat anti-mouse IgG-, IgG 1 -, IgG 2c -(the isoform of IgG 2a in C57BL/6 mice), IgG 2b -, or IgE-specific antibodies purchased from Bethyl Laboratories (Montgomery, Tex).</s><s>After incubation with the 3,39,5,59-tetramethylbenzidine substrate (BD Biosciences, San Diego, Calif) or in Fig <ref type="figure" target="#fig_6">E1</ref> with Femto Substrate (Thermo Fisher Scientific), OD was measured at 450 nm or 425 nm, respectively.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Bet v 1-and tetanus toxin-reactive ELISA</head><p><s>ELISA plates were coated with 10 mg/mL Bet v 1 or 2.5 Lf/mL tetanus toxin (National Institute for Biological Standards and Control, Potters Bar, United Kingdom) to measure Bet v 1-or tetanus toxin-specific IgE, IgG, IgG 1 , or IgG 4 levels.</s><s>Unless indicated otherwise, plates were incubated with 1:100 diluted serum or plasma, and bound antibodies were detected with anti-human IgG (clone HP-6017, mouse IgG 2a ) or IgG 1 (clone HP-6001, mouse IgG 2b ) and horseradish peroxidase-conjugated polyclonal goat anti-mouse IgG 2a or anti-mouse IgG 2b secondary antibodies, respectively; horseradish peroxidase-conjugated anti-human IgG4 (clone HP-6025, mouse IgG 1 ); or horseradish peroxidase-conjugated polyclonal anti-human IgE (all antibodies from Bethyl Laboratories).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>In vitro desialylation and/or degalactosylation of IgG antibodies</head><p><s>Purified (native) IgG antibodies were desialylated with sialidase A (#GK80040; ProZyme, Hayward, Calif) or additionally degalactosylated with b(1-4)-galactosidase (Streptococcus pneumoniae; #GKX-5014, ProZyme).</s><s>Anti-TNP and anti-Bet v 1 reactivities of differently glycosylated antibodies were analyzed by means of ELISA.</s><s>IgG Fc N-glycosylation was analyzed by using HPLC.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>In vitro galactosylation and/or sialylation of IgG antibodies</head><p><s>In vitro galactosylation and sialylation of purified IgG antibodies was performed in a 2-step procedure, as previously described.</s><s><ref type="bibr">E16,E35,E38</ref> Briefly, purified (native) antibodies were galactosylated with human b1,4-galactosyltransferase and UDP-galactose or subsequently additionally sialylated with human a2,6-sialyltransferase and CMP-sialic acid (substrates and transferases were purchased from Calbiochem [Nottingham, United Kingdom] or Roche [Basel, Switzerland]), or a2,6-sialyltransferase was produced, as previously described.</s><s><ref type="bibr">E39,E40</ref> The anti-TNP reactivity of differently glycosylated antibodies was tested by using ELISA.</s><s>IgG Fc N-glycosylation was analyzed by using HPLC.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Glycan analysis of purified IgG antibodies by using HPLC</head><p><s>N-glycans were isolated from purified IgG samples by means of hydrolysis with recombinant endoglycosidase S (EndoS) from Streptococcus pyogenes.</s><s><ref type="bibr">E35,E38,E41</ref> EndoS cleaves the Fc N-glycans of IgG antibodies at the chitobiose core between the first and second N-acetylglucosamine (GlcNAc; Fig 1, A, and Fig E1).</s><s>The resulting N-glycans were purified by using solid-phase extraction with homemade Carbograph graphitized carbon columns (Fisher Scientific, Hampton, NH) E42 and labeled with anthranilamide (Sigma-Aldrich), as previously described.</s><s><ref type="bibr">E43</ref> The hydrophilic interaction liquid chromatography-HPLC with labeled glycans was performed on a Dionex Ultimate 3000 (Thermo Fischer Scientific, Waltham, Mass) by using an Xbridge XP BEH Glycan column (2.5 mm, 100 3 4.6 mm i.d.; Waters,  Milford, Mass).</s><s>Peak identity was confirmed by analyzing the collected peak fractions by means of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, as previously described.</s><s><ref type="bibr">E35,E38</ref> Glycans with human or murine sialic acids (human N-acetylneuraminic acid or murine N-glycolylneuraminic acid) had different retention times.</s><s>Based on the terminal sugar moiety, peaks were assigned to one of the following 9 groups: G0 1 bisecting GlcNAc, G0 2 bisecting GlcNAc, G1 1 bisecting GlcNAc, G1 2 bisecting GlcNAc, G2 1 bisecting GlcNAc, G2 2 bisecting GlcNAc, G1S1, G2S1, and G2S2.</s><s>Peaks containing both sialic acid and bisecting GlcNAc were not detected.</s><s>Calculated proportions of the bisecting GlcNAc versions of G0, G1, and G2 were added to percentages of the G0, G1, and G2 versions without bisecting GlcNAc, respectively, to present 6 groups totaling 100%: G0, G1, G2, G1S1, G2S1, and G2S2 (Figs <ref type="figure" target="#fig_7">1 and 2 and Figs  E1-E3</ref>).</s><s>Mouse IgG antibodies rarely have a bisecting GlcNAc, whereas 10% to 15% of human IgG antibodies have a bisecting GlcNAc.</s><s>Because more Fc glycans of total serum IgG from untreated C57BL/6 mice are sialylated than pooled serum IgG from healthy human donors (IVIG), percentages of sialylation of murine and human IgG antibodies cannot be directly compared.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>IgG Fc subclass glycopeptide analysis</head><p><s>In contrast to only small differences in Fc glycosylation patterns between human IgG subclasses in the same sample, <ref type="bibr">E30,E31</ref> the Fc glycosylation pattern of murine IgG subclass antibodies in the same sample highly differ.</s><s><ref type="bibr">E32</ref> Accordingly, polyclonal murine IgG Fc subclass glycopeptides were analyzed, as described previously.</s><s><ref type="bibr">E44</ref> In short, OVA-specific IgG antibodies were cleaved with trypsin, and IgG 1 and IgG 2 (IgG 2b and IgG 2c , both cannot be distinguished because of the comparable peptide sequence) Fc glycopeptides were analyzed by using nano-liquid chromatography mass spectrometry.</s><s>Glycopeptide signals were assigned and quantified, <ref type="bibr">E32</ref> and IgG 1 versus IgG 2 ratios and their summarized G0, G1, G2, G1S1, G2S1, and G2S2 forms were calculated, as described above.</s><s>Glycans without fucose or with bisecting GlcNAc were hardly detected.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Experimental passive IgE-mediated systemic anaphylaxis</head><p><s>On day 0, female mice were primed intravenously with 10 mg of IgE anti-TNP (clone IgEL a2; ATCC-TIB-142 E36 ).</s><s>Mice were treated with various amounts of IgG subclass anti-TNP mAbs 22.5 hours later and challenged intravenously with 1 mg of TNP-OVA 1.5 hours later.</s><s>Changes in body core/rectal temperature were measured to assess the severity of systemic anaphylaxis (Physitemp BAT-12R thermometer; Science Products GmbH, Hofheim, Germany).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Experimental passive IgG-mediated systemic anaphylaxis</head><p><s>Two hundred micrograms of IgG subclass anti-TNP or 100 mg of purified OVA-specific IgG antibodies were injected intravenously into female C57BL/ 6 mice.</s><s>Twenty-four hours later, the mice were challenged intravenously with 20 mg of TNP-OVA.</s><s>Anaphylaxis severity was measured by determining the changes in the body core/rectal temperature.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>a-SignR1 treatment</head><p><s>The a-SignR1 (clone 22D1) mAb was purchased from BioXCell (West Lebanon, NH).</s><s>One hundred micrograms of this antibody was injected intravenously 1 hour before IgG subclass anti-TNP antibody injection to induce SignR1 internalization.</s><s><ref type="bibr">E17</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Human neutrophil activation assay</head><p><s>Human neutrophils were isolated from heparinized peripheral blood from healthy adult donors, as previously described.</s><s><ref type="bibr">E45</ref> To generate plate-bound, immobilized immune complexes, 50 mg/mL Bet v 1 in 0.05 mmol/L carbonate/bicarbonate buffer (pH 9.6) was coated on Lumitrac 600 96-well plates (Greiner Bio-one, Frickenhausen, Germany) for 1 hour, followed by an 18-hour incubation with desialylated or native purified serum IgG (200 mg/200 mL per well).</s><s>Freshly isolated neutrophils in chemiluminescence medium (RPMI medium without phenol red and sodium bicarbonate containing 20 nmol/L HEPES and 0.06 mmol/L Luminol; 2 3 10 6 cells/ mL) were seeded in the plates with the immobilized immune complexes (2 3 10 5 cells per well).</s><s>The sum of intracellular and extracellular reactive oxygen species (ROS), a sign of neutrophil activation, was measured (duplicate measurements) by using luminol-amplified chemiluminescence for 1.5 hours at 378C with FluoStar Omega (BMG Labtech, Ortenberg, Germany).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>Analysis of OVA injection data and ROS data (area under the curve) was performed with the Student t test.</s><s>Body core/rectal temperature data (area under the curve) were analyzed by using 1-way ANOVA.</s><s>Longitudinal analyses of the Bet v 1-specific antibody titers, skin prick tests, and clinical scores were performed by using the Wilcoxon signed-rank test.</s><s>All experiments were not blinded.</s><s>If not stated otherwise, data were expressed as means 6 SEMs.</s><s>In all experiments normal distribution was assumed.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc><div><p><s>, and see Fig E1).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc><div><p><s>the IgG glycosylation pattern (Fig 1, D and E) and IgG subclass (studied by comparing IgG 1 , IgG 2a , and IgG 2b anti-TNP class-switch variant mAbs with identical V[D]J sequences; Fig E1, G, and data not shown) E20 had only a slight effect on the extent of inhibition.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head></head><label></label><figDesc><div><p><s>Fig 1, G and H, and see Fig E1).</s><s>Desialylated plus degalactosylated IgG 2a and IgG 2b subclass anti-TNP switch variant mAbs induced more severe anaphylaxis than desialylated plus degalactosylated switch variant and low-galactosylated (H5) IgG 1 mAbs (IgG 2a 5 IgG 2b &gt; IgG 1 , see Fig E1). 4 IgG 1 -mediated anaphylaxis was inhibited by means of galactosylation and especially by means of additional sialylation (Fig 1, G); sialylation also significantly reduced the anaphylaxis potential of IgG 2b and tended to reduce that of IgG 2a (Fig 1, G). Sialylation even reduced the increased anaphylaxis potential of IgG 1 in FcgRIIb-deficient mice (Fig 1, H), 4 suggesting the importance of additional/other inhibitory mechanisms of IgG 1 sialylation, such as one dependent on the C-type lectin receptor SignR1 (specific ICAM-3 grabbing nonintegrin-related 1) (Fig 1, I).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>1 (</head><label>1</label><figDesc><div><p><s>Fig 2, H, and see Fig E3).E32  Because alum and MPLA induced higher galactosylation and sialylation levels of both OVA-specific IgG1 and IgG 2(b) than OVA-eCFA (Fig 2, H), MPLA, with the highest ratio of IgG 2(b) , induced the highest levels of total IgG galactosylation and sialylation, as determined by using HPLC glycan analysis (Fig 2, I, and see Fig E3).</s><s>Consistently, only 100 mg of purified OVA-specific IgG antibodies from the OVA-eCFA group, but not from the OVA-MPLA group, induced IgG-mediated anaphylaxis (Fig 2, J).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>1 3</head><label>1</label><figDesc><div><p><s>w -g a l Ig G 1 (H 5 ) / d e -g a l Ig G 1 , 2 a a n d 2 b (s v ); y e llo w :g a l Ig G ; r e d /g r e e n :s ia l Ig G -/+ α -S ig n R</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head>FIG 1 .</head><label>1</label><figDesc><div><p><s>FIG 1.</s><s>Effect of differently glycosylated IgG subclass antibodies on IgE-and IgG-mediated murine anaphylaxis.</s><s>A, The conserved biantennary N-glycan (4 N-acetylglucosamines [dark blue] and 3 mannoses [green]) at Asn 297 in the IgG Fc part can be modified by fucose (red), bisecting GlcNAc (light blue), galactose (G; yellow), and sialic acid (S; magenta).</s><s>The cleavage site of EndoS used for IgG glycan analysis is depicted.</s><s>B, Experimental design of IgE-mediated anaphylaxis as done in Fig 1, D and E. C, Fc glycosylation profiles of the differently glycosylated murine IgG 1 anti-TNP mAbs (clone H5) used in the murine experiments.</s><s>Native 5 low-galactosylated (low-gal), in vitro galactosylated (gal), or galactosylated plus sialylated (sial).</s><s>D and E, Inhibition of IgE-mediated temperature decrease by differently glycosylated IgG 1 anti-TNP mAbs (H5) in wild-type (Fig 1, D) and FcgRIIb-deficient (Fig 1, E) mice (in each graph: no IgG, n 5 8-10; low-gal, n 5 8-10; gal, n 5 5; sial, n 5 5).</s><s>Symbols represent means.</s><s>One of 2 independent experiments is shown.</s><s>ns, Not significant.</s><s>F, Experimental design of IgG-mediated anaphylaxis as done in Fig 1, G-I.</s><s>G-I, Decrease in body temperature induced with differently glycosylated IgG subclass anti-TNP mAbs (IgG1 [clone H5] or IgG2a and IgG2b switch variants [sv]) in wild-type (Fig 1, G-I) or FcgRIIb-deficient (Fig 1, H) mice without (Fig 1, G-I) or with a-SignR1 treatment (Fig 1, I).</s><s>de-gal, In vitro desialylated plus degalactosylated.</s><s>Fig 1, G, Pooled data (n 5 10-15) from independent experiments with 5 per group per experiment.</s><s>Fig 1, H and I, One of 2 independent experiments is shown.</s><s>**P &lt; .01 and ***P &lt; .001.</s><s>i.v., Intravenous.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_7"><head>FIG 2 .</head><label>2</label><figDesc><div><p><s>FIG 2. Bet v 1-specific serum IgG Fc glycosylation of untreated and treated allergic patients and influence of different adjuvants on IgG Fc glycosylation.</s><s>A, Serum titers of Bet v 1-specific IgG 1 and IgG 4 from untreated subjects (season, n 5 8; no season, n 5 6 1 11 [AIT-treated, month 0]) and AIT-treated (n 5 11) patients with birch pollen allergy.</s><s>Black line, mean; gray columns, pollen season.</s><s>Green data points depict the 5 AIT-treated patients who were selected for the glycan analysis in Fig 2, B and C, and Fig E2, whereas red data points depict the 3 samples (patient 5 at months 12 [5-12], 5-36, and 21-18) that were chosen for in vitro desialylation and neutrophil activation in Fig 2, B-E, and Fig E2.</s><s>One of 2 independent ELISAs is shown.</s><s>B and C, Percentage of agalactosylated (G0; Fig 1, B) and sialylated (Fig 1, C) glycans from purified Bet v 1-specific IgG antibodies of untreated (season, n 5 5; no season, n 5 5 1 5 [AIT-treated, month 0]) and the 5 selected AIT-treated patients and from IVIG and purified native and in vitro desialylated (de-sial) total serum IgG from patient samples 5-12, 5-36, and 21-18.</s><s>Filled areas indicate levels of agalactosylated (G0) or sialylated IgG autoantibodies in patients with rheumatoid arthritis (RA) for comparison.</s><s>E14 D and E, Human neutrophil activation assay: experimental setup (Fig 2, D) and reactive oxygen species (ROS) production (Fig 2, E) after activation with native or in vitro desialylated Bet v 1-specific IgG antibodies of patient 5 (P5 m36).</s><s>Black line, No IgG.</s><s>One of 2 independent ROS assays is shown.</s><s>F-J, Effect of distinct adjuvants (eCFA, alum, or MPLA) on induction of OVA-specific serum IgG antibodies.</s><s>Fig 2, F, Experimental design.</s><s>Fig 2, G, IgG 1 and IgG 2 (IgG 2b 1 IgG 2c ; neither can be distinguished by means of glycopeptide analysis because of the comparable peptide sequence) frequencies in purified OVA-specific IgG antibodies, as determined by using glycopeptide analysis.</s><s>H and I, IgG 1 and IgG 2 or total IgG Fc sialylation profiles of pooled and purified OVA-specific IgG antibodies, as determined by glycopeptide (Fig 2, H) or total IgG glycan (Fig 2, I) analysis.</s><s>J, IgG-mediated anaphylaxis as described in Fig 1, F, with 100 mg of pooled and purified OVA-specific serum IgG antibodies (n 5 4-5 per group).</s><s>Symbols represent means.</s><s>*P &lt; .05,</s><s>**P &lt; .01,</s><s>and ***P &lt; .001.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_8"><head></head><label></label><figDesc><div><p><s>FIG E1.</s><s>Generation, analysis, and function of differently glycosylated murine IgG subclass antibodies.</s><s>A, Conserved IgG biantennary N-glycan at Asn297 can be modified by fucose (red), bisecting GlcNAc (light blue), galactose (G; yellow), and sialic acid (S; magenta).</s><s>B, Exemplary HPLC glycan peaks of in vitro desialylated plus degalactosylated (de-gal), galactosylated (gal), or galactosylated plus sialylated (sial) IgG 2a anti-TNP mAbs(switch variant [sv]).</s><s>C, Fc glycosylation profiles of the differently glycosylated murine IgG 1 , IgG 2a , and IgG 2b anti-TNP switch variants that were used in the murine experiments.</s><s>Native 5 low-galactosylated (low-gal).</s><s>D-F, Anti-TNP IgG 1 affinity ELISA.Fig 1, D, Experimental setup.</s><s>ELISA plates were coated with TNP-BSA alone or with increasing amounts of BSA, as indicated as ratios (TNP-BSA/BSA 5 1:0, 1:10 or 1:1000).</s><s>Fig 1, E, Modification of the Fc glycan of IgG 1 anti-TNP mAbs (clone H5) did not change affinity.</s><s>Fig 1, F, IgG 1 anti-TNP clone H5 has a higher affinity than the IgG 1 anti-TNP switch variant.</s><s>One of 2 independent ELISA experiments is shown in Fig 1, E and F. G, IgE-mediated anaphylaxis, as described in Fig 1, B, with 10 mg of low-gal IgG subclass anti-TNP mAbs (switch variants) in C57BL/6 wildtype or FcgRIIb-deficient mice.</s><s>One of 2 independent experiments is shown.</s><s>H, IgG-mediated anaphylaxis, as described in Fig 1, F and G, with low-gal (H5) or de-gal (switch variants) IgG subclass anti-TNP mAbs in wild-type mice.</s><s>For each IgG subclass antibody, n 5 10-15.</s><s>Symbols represent means.</s><s>Pooled data are from independent experiments with n 5 5 per group per experiment.</s><s>*P &lt; .05 and **P &lt; .01.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_9"><head>Fig E2 ,</head><label>E2</label><figDesc><div><p><s>Fig E2, I, K, and L. E, IgG 4 /IgG 1 ratios (OD [IgG 4 ]/OD [IgG 1 ]) as calculated from IgG 1 and IgG 4 ELISA data in Fig 2, A. F, Protocol for purification and EndoS treatment of Bet v 1-specific serum IgG antibodies.</s><s>G and H, Amplification and purification of Bet v 1-specific IgG antibodies was verified through anti-Bet v 1 ELISA (Fig E2, G) and anti-tetanus toxin ELISA (Fig E2, H) to document the exclusion of IgG antibodies that lack Bet v 1 specificity, here exemplified for patient P2 (month 36).</s><s>I and J, Percentages of different glycans (G0, G1, G2, G1S1, G2S1, and G2S2) from summarized (Fig E2, I) and single human (Fig E2, J) samples from purified Bet v 1-specific IgG antibodies of untreated (season, n 5 5; no season, n 5 5 1 5 [AIT treated, month 0]) and the 5 randomly selected AIT-treated patients and from IVIG and purified native and in vitro desialylated total serum IgG from patient samples 5-12, 5-36, and 21-18.</s><s>K and L, Human neutrophil activation assay, as described in Fig 2, D and E. Experimental setup (Fig E2, K) and ROS production (Fig E2, L) after activation with native or in vitro desialylated (de-sial) Bet v 1-specific IgG antibodies of patient samples P5 m12 and P21 m18.</s><s>Black line, No IgG.</s><s>One of at least 2 independent ROS assays is shown for each patient.</s><s>*P &lt; .05,</s><s>**P &lt; .01,</s><s>and ***P &lt; .001.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_10"><head>=</head><label></label><figDesc><div><p></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head></head><label></label><figDesc><div><p><s>on IgG subclass and Fc glycosylation profiles in OVA-immunized mice (Fig 2, F, and see Fig E3).</s><s>eCFA induced the highest IgG titer (eCFA &gt; MPLA 5 alum; see Fig E3, C), but all 3 immunizations induced predominantly IgG 1</s></p></div></figDesc><table><row><cell>(alum/94% &gt; eCFA/81% &gt; MPLA/65%), followed by IgG 2b</cell></row><row><cell>and hardly any IgG 2c (IgG 2 [IgG 2b 1 IgG 2c ]: MPLA/</cell></row><row><cell>35% &gt; eCFA/19% &gt; alum/6%; Fig 2, G, and see Fig E3, C), the</cell></row><row><cell>functions of which depend on galactosylation (only IgG 1 ) and</cell></row><row><cell>sialylation (IgG 1 and at least in part IgG 2b ; Fig 1, G).</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 1 LETTERS TO THE EDITOR 402.e1</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 1 LETTERS TO THE EDITOR 402.e3</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 1 LETTERS TO THE EDITOR 402.e7</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0" />
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>* * *  ( ) ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( )</s></p><p><s>A D C 100 µg of OVA plus (eCFA, alum or MPLA) i.p.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Advances in allergen immunotherapy: aiming for complete tolerance to allergens</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Akdis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Akdis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci Transl Med</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="280" to="286" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Human IgE-independent systemic anaphylaxis</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">D</forename><surname>Finkelman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Khodoun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Strait</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">137</biblScope>
			<biblScope unit="page" from="1674" to="1680" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and Fc gamma RIIb cross-linking</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>Strait</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Morris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">D</forename><surname>Finkelman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<biblScope unit="page" from="833" to="841" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">IgG subclasses determine pathways of anaphylaxis in mice</title>
		<author>
			<persName><forename type="first">H</forename><surname>Beutier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Gillis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Iannascoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Godon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>England</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Sibilano</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">139</biblScope>
			<biblScope unit="page" from="269" to="280" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note>e7</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Tolerance induction with T cell-dependent protein antigens induces regulatory sialylated IgGs</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Oefner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Winkler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hess</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Lorenz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Holecska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Huxdorf</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">129</biblScope>
			<biblScope unit="page" from="1647" to="1655" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">T cell-independent B cell activation induces immunosuppressive sialylated IgG antibodies</title>
		<author>
			<persName><forename type="first">C</forename><surname>Hess</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Winkler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Lorenz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Holecska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Blanchard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Eiglmeier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="3788" to="3796" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">The carbohydrate switch between pathogenic and immunosuppressive antigen-specific antibodies</title>
		<author>
			<persName><forename type="first">M</forename><surname>Collin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ehlers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Exp Dermatol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="511" to="514" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Type I and type II Fc receptors regulate innate and adaptive immunity</title>
		<author>
			<persName><forename type="first">A</forename><surname>Pincetic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bournazos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Dilillo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Maamary</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">T</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Dahan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Immunol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="707" to="716" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies</title>
		<author>
			<persName><forename type="first">C</forename><surname>M€ Obs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ipsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mayer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Slotosch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Petersen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>W€ Urtzen</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jaci.2017.06.021</idno>
		<ptr target="http://dx.doi.org/10.1016/j.jaci.2017.06.021" />
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">130</biblScope>
			<biblScope unit="page" from="1108" to="1116" />
			<date type="published" when="2012-07-18">2012. July 18, 2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">IgG4 inhibits peanut-induced basophil and mast cell activation in peanut-tolerant children sensitized to peanut major allergens</title>
		<author>
			<persName><surname>References E1</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Santos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">K</forename><surname>James</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">T</forename><surname>Bahnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Shamji</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Couto-Francisco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Islam</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">135</biblScope>
			<biblScope unit="page" from="1249" to="1256" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">A single glycan on IgE is indispensable for initiation of anaphylaxis</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">T</forename><surname>Shade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Platzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Washburn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Mani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename><surname>Bartsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Conroy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Exp Med</title>
		<imprint>
			<biblScope unit="volume">212</biblScope>
			<biblScope unit="page" from="457" to="467" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Advances and highlights in mechanisms of allergic disease in 2015</title>
		<author>
			<persName><forename type="first">P</forename><surname>Wawrzyniak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Akdis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">D</forename><surname>Finkelman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Rothenberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">137</biblScope>
			<biblScope unit="page" from="1681" to="1696" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation</title>
		<author>
			<persName><forename type="first">D</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Kepley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Saxon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Med</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="518" to="521" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Oral immunotherapy induces IgG antibodies that act through FcgRIIb to suppress IgE-mediated hypersensitivity</title>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">T</forename><surname>Burton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Logsdon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Medina-Tamayo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Abdel</forename><forename type="middle">-</forename><surname>Gadir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Noval</forename><surname>Rivas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">134</biblScope>
			<biblScope unit="page" from="1310" to="1317" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>e6</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Association of protamine IgE and IgG antibodies with life-threatening reactions to intravenous protamine</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Weiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Nyhan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">K</forename><surname>Peng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Horrow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lowenstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hirshman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">320</biblScope>
			<biblScope unit="page" from="886" to="892" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">L</forename><surname>Hazenbos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Gessner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Hofhuis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kuipers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">A</forename><surname>Heijnen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunity</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="181" to="188" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Assessment of the cardiopulmonary changes, mast cell degranulation, and death associated with active or IgE-or IgG1-dependent passive anaphylaxis</title>
		<author>
			<persName><forename type="first">I</forename><surname>Miyajima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Dombrowicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">V</forename><surname>Ravetch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Kinet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Galli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="901" to="914" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note>Systemic anaphylaxis in the mouse can be mediated largely through IgG1 and Fc gammaRIII</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Identification of markers that distinguish IgE-from IgG-mediated anaphylaxis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Khodoun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Strait</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Armstrong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Yanase</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">D</forename><surname>Finkelman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci U S A</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="page" from="12413" to="12418" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">IgG-mediated anaphylaxis to a synthetic long peptide vaccine containing a B cell epitope can be avoided by slow-release formulation</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">D</forename><surname>Quakkelaar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Fransen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">W</forename><surname>Van Maren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Vaneman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">M</forename><surname>Loof</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Van Heiningen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">192</biblScope>
			<biblScope unit="page" from="5813" to="5820" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Mouse and human FcR effector functions</title>
		<author>
			<persName><forename type="first">P</forename><surname>Bruhns</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunol Rev</title>
		<imprint>
			<biblScope unit="volume">268</biblScope>
			<biblScope unit="page" from="25" to="51" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Mechanisms of anaphylaxis in human low-affinity IgG receptor locus knock-in mice</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Gillis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>J€ Onsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Mancardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Tu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Beutier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Van Rooijen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">139</biblScope>
			<biblScope unit="page" from="1253" to="1265" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note>e14</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">IgG subclasses and allotypes: from structure to effector functions</title>
		<author>
			<persName><forename type="first">G</forename><surname>Vidarsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Dekkers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Rispens</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Front Immunol</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">520</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">U</forename><surname>Scherer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Van Der Woude</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ioan-Facsinay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Bannoudi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Trouw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="1620" to="1629" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Sialylation converts arthritogenic IgG into inhibitors of collagen-induced arthritis</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Ohmi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Ise</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Harazono</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Takakura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Fukuyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Baba</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Commun</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">11205</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Kaneko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Nimmerjahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">V</forename><surname>Ravetch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">313</biblScope>
			<biblScope unit="page" from="670" to="673" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Identification of a receptor required for the anti-inflammatory activity of IVIG</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Anthony</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Wermeling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Karlsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">V</forename><surname>Ravetch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci U S A</title>
		<imprint>
			<biblScope unit="volume">105</biblScope>
			<biblScope unit="page" from="19571" to="19578" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Anthony</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kobayashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Wermeling</surname></persName>
		</author>
		<author>
			<persName><surname>Rav</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">475</biblScope>
			<biblScope unit="page" from="110" to="113" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of Fc gamma RIIB and dectin-1</title>
		<author>
			<persName><forename type="first">E19</forename><surname>Karsten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Pandey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Figge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kilchenstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Rosas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Med</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="1401" to="1406" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">IgG1 protects against renal disease in a mouse model of cryoglobulinaemia</title>
		<author>
			<persName><forename type="first">E20</forename><surname>Strait</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>Posgai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Mahler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Barasa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Jacob</forename><surname>Co</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">517</biblScope>
			<biblScope unit="page" from="501" to="504" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Birch pollen immunotherapy leads to differential induction of regulatory T cells and delayed helper T cell immune deviation</title>
		<author>
			<persName><surname>E21</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>M€ Obs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Slotosch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>L€ Offler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jakob</forename><forename type="middle">T</forename><surname>Hertl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Pf€</forename></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">184</biblScope>
			<biblScope unit="page" from="2194" to="2203" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Monitoring the epitope recognition profiles of IgE, IgG1, and IgG4 during birch pollen immunotherapy</title>
		<author>
			<persName><forename type="first">B</forename><surname>Gepp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Lengger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>M€ Obs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Pf€ Utzner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Radauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bohle</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">137</biblScope>
			<biblScope unit="page" from="1600" to="1603" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>e1</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">The diversity of Bet v 1-specific IgG4 antibodies remains mostly constant during the course of birch pollen immunotherapy</title>
		<author>
			<persName><forename type="first">B</forename><surname>Subbarayal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Schiller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>M€ Obs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Pf€ Utzner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Jahn-Schmid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Gepp</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">136</biblScope>
			<biblScope unit="page" from="1680" to="1682" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>e3</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response</title>
		<author>
			<persName><surname>E24. Aalberse</surname></persName>
		</author>
		<author>
			<persName><surname>Rc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Van Der Gaag</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Van Leeuwen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">130</biblScope>
			<biblScope unit="page" from="722" to="726" />
			<date type="published" when="1983">1983</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Immunological mechanisms of allergen-specific immunotherapy</title>
		<author>
			<persName><surname>E25</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Larch E</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Akdis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Valenta</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Immunol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="761" to="771" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Adjuvants for immunotherapy</title>
		<author>
			<persName><forename type="first">O</forename><surname>Pfaar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Cazan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Klimek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Larenas-Linnemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Calderon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="648" to="657" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen</title>
		<author>
			<persName><forename type="first">P</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Holdich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Fischer Von Weikersthal-Drachenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Huber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">133</biblScope>
			<biblScope unit="page" from="e1" to="2" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: lessons from the past and novel mechanisms of action for the future</title>
		<author>
			<persName><forename type="first">R</forename><surname>Valenta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Campana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Focke-Tejkl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Niederberger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">137</biblScope>
			<biblScope unit="page" from="351" to="357" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Antigen-specific antibody glycosylation is regulated via vaccination</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Mahan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Jennewein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Suscovich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dionne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tedesco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Chung</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS Pathog</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">e1005456</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Association between galactosylation of immunoglobulin G and improvement of rheumatoid arthritis during pregnancy is independent of sialylation</title>
		<author>
			<persName><forename type="first">A</forename><surname>Bondt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Selman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Deelder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Hazes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Willemsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wuhrer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Proteome Res</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="4522" to="4531" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Effects of allergic diseases and age on the composition of serum IgG glycome in children</title>
		<author>
			<persName><forename type="first">M</forename><surname>Pezer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Stambuk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Perica</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Razdorov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Banic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Vuckovic</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci Rep</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">33198</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">The N-glycosylation of mouse IgG-Fc differs between IgG subclasses and strains</title>
		<author>
			<persName><forename type="first">N</forename><surname>De Haan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Reiding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kri Sti C</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Alh</forename><surname>Ederveen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Lauc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wuhrer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Front Immunol</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">608</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies</title>
		<author>
			<persName><surname>E33</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>M€ Obs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ipsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mayer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Slotosch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Petersen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>W€ Urtzen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">130</biblScope>
			<biblScope unit="page" from="1108" to="1116" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>e6</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice</title>
		<author>
			<persName><forename type="first">T</forename><surname>Takai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ono</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hikida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ohmori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">V</forename><surname>Ravetch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">379</biblScope>
			<biblScope unit="page" from="346" to="349" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">T cell-independent B cell activation induces immunosuppressive sialylated IgG antibodies</title>
		<author>
			<persName><forename type="first">C</forename><surname>Hess</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Winkler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Lorenz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Holecska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Blanchard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Eiglmeier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="3788" to="3796" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Thirteen hybridomas secreting hapten-specific immunoglobulin E from mice with Iga or Igb heavy chain haplotype</title>
		<author>
			<persName><forename type="first">E36</forename><surname>Rudolph</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Burrows</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Wabl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Immunol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="527" to="529" />
			<date type="published" when="1981">1981</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">IgG-mediated enhancement of antibody responses is low in Fc receptor gamma chain-deficient mice and increased in Fc gamma RII-deficient mice</title>
		<author>
			<persName><forename type="first">S</forename><surname>Wernersson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Karlsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dahlstr€ Om</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mattsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Verbeek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Heyman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">163</biblScope>
			<biblScope unit="page" from="618" to="622" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Tolerance induction with T cell-dependent protein antigens induces regulatory sialylated IgGs</title>
		<author>
			<persName><forename type="first">E38</forename><surname>Oefner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Winkler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hess</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lorenz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Holecska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Huxdorf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">129</biblScope>
			<biblScope unit="page" from="1647" to="1655" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">NMR characterization of immunoglobulin G Fc glycan motion on enzymatic sialylation</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Barb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Meng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename><surname>Moremen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Prestegard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochemistry</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="4618" to="4626" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Enzymatic basis for N-glycan sialylation: structure of rat a2,6-sialyltransferase (ST6GAL1) reveals conserved and unique features for glycan sialylation</title>
		<author>
			<persName><forename type="first">L</forename><surname>Meng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Forouhar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Thieker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ramiah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Moniz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">288</biblScope>
			<biblScope unit="page" from="34680" to="34698" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Effect of SpeB and EndoS from Streptococcus pyogenes on human immunoglobulins</title>
		<author>
			<persName><forename type="first">M</forename><surname>Collin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ols En</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Infect Immun</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="7187" to="7189" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">A general approach to desalting oligosaccharides released from glycoproteins</title>
		<author>
			<persName><forename type="first">E42</forename><surname>Packer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">H</forename><surname>Lawson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Jardine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Redmond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Glycoconj J</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="737" to="747" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Nonselective and efficient fluorescent labeling of glycans using 2-amino benzamide and anthranilic acid</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Bigge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Bruce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">N</forename><surname>Goulding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Charles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Parekh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Anal Biochem</title>
		<imprint>
			<biblScope unit="volume">230</biblScope>
			<biblScope unit="page" from="229" to="238" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Antigen specificity determines anti-red blood cell IgG-Fc alloantibody glycosylation and thereby severity of haemolytic disease of the fetus and newborn</title>
		<author>
			<persName><forename type="first">E44</forename><surname>Sonneveld</surname><genName>ME</genName></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Koelewijn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>De Haas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Admiraal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Plomp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Koeleman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Haematol</title>
		<imprint>
			<biblScope unit="volume">176</biblScope>
			<biblScope unit="page" from="651" to="660" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Phagocytosis of apoptotic cells by neutrophil granulocytes: diminished proinflammatory neutrophil functions in the presence of apoptotic cells</title>
		<author>
			<persName><forename type="first">L</forename><surname>Esmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Idel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sarkar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Hellberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Behnen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>M€ Oller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">184</biblScope>
			<biblScope unit="page" from="391" to="400" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
